Carfilzomib and dexamethasone vs bortezomib and dexamethasone
in patients with relapsed multiple myeloma: results of the
phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

J 2017

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

LUDWIG, H.; M.A. DIMOPOULOS; P. MOREAU; W.J. CHNG; H. GOLDSCHMIDT et. al.

Basic information

Original name

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

Authors

Edition

LEUKEMIA & LYMPHOMA, LONDON, INFORMA HEALTHCARE, 2017, 1042-8194

Other information

Language

English

Type of outcome

Article in a journal

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

is not subject to a state or trade secret

References:

URL

Impact factor

Impact factor: 2.644

Organization unit

Faculty of Medicine

DOI

https://doi.org/10.1080/10428194.2017.1298755

UT WoS

000404572000031

Keywords in English

Carfilzomib; dexamethasone; bortezomib

Abstract

In the original language

Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.

Cite

LUDWIG, H.; M.A. DIMOPOULOS; P. MOREAU; W.J. CHNG; H. GOLDSCHMIDT; Roman HÁJEK; T. FACON; Luděk POUR; R. NIESVIZKY; A. ORIOL; L. ROSINOL; A. SUVOROV; G. GAIDANO; T. PIKA; K. WEISEL; V. GORANOVA-MARINOVA; A. PALUMBO; H.H. GILLENWATER; N. MOHAMED; S. AGGARWAL; S.B. FENG and D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. LEUKEMIA & LYMPHOMA. LONDON: INFORMA HEALTHCARE, 2017, vol. 58, No 10, p. 2501-2504. ISSN 1042-8194. Available from: https://doi.org/10.1080/10428194.2017.1298755.

@article{1398977,
   author = {Ludwig, H. and Dimopoulos, M.A. and Moreau, P. and Chng, W.J. and Goldschmidt, H. and Hájek, Roman and Facon, T. and Pour, Luděk and Niesvizky, R. and Oriol, A. and Rosinol, L. and Suvorov, A. and Gaidano, G. and Pika, T. and Weisel, K. and GoranovaandMarinova, V. and Palumbo, A. and Gillenwater, H.H. and Mohamed, N. and Aggarwal, S. and Feng, S.B. and Joshua, D.},
   article_location = {LONDON},
   article_number = {10},
   doi = {https://doi.org/10.1080/10428194.2017.1298755},
   keywords = {Carfilzomib; dexamethasone; bortezomib},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup},
   url = {http://dx.doi.org/10.1080/10428194.2017.1298755},
   volume = {58},
   year = {2017}
}

TY  - JOUR
ID  - 1398977
AU  - Ludwig, H. - Dimopoulos, M.A. - Moreau, P. - Chng, W.J. - Goldschmidt, H. - Hájek, Roman - Facon, T. - Pour, Luděk - Niesvizky, R. - Oriol, A. - Rosinol, L. - Suvorov, A. - Gaidano, G. - Pika, T. - Weisel, K. - Goranova-Marinova, V. - Palumbo, A. - Gillenwater, H.H. - Mohamed, N. - Aggarwal, S. - Feng, S.B. - Joshua, D.
PY  - 2017
TI  - Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup
JF  - LEUKEMIA & LYMPHOMA
VL  - 58
IS  - 10
SP  - 2501-2504
EP  - 2501-2504
PB  - INFORMA HEALTHCARE
SN  - 10428194
KW  - Carfilzomib
KW  - dexamethasone
KW  - bortezomib
UR  - http://dx.doi.org/10.1080/10428194.2017.1298755
L2  - http://dx.doi.org/10.1080/10428194.2017.1298755
N2  - Article Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup.
ER  -

LUDWIG, H.; M.A. DIMOPOULOS; P. MOREAU; W.J. CHNG; H. GOLDSCHMIDT; Roman HÁJEK; T. FACON; Luděk POUR; R. NIESVIZKY; A. ORIOL; L. ROSINOL; A. SUVOROV; G. GAIDANO; T. PIKA; K. WEISEL; V. GORANOVA-MARINOVA; A. PALUMBO; H.H. GILLENWATER; N. MOHAMED; S. AGGARWAL; S.B. FENG and D. JOSHUA. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2017, vol.~58, No~10, p.~2501-2504. ISSN~1042-8194. Available from: https://doi.org/10.1080/10428194.2017.1298755.

Přehled o publikaci